Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE ...
Also, don’t miss ✨LIVE MUSIC TONIGHT✨ on the Merrick Patch calendar ...
And check out Message in the Stars on the East Meadow Patch calendar ...
February 11, 2026 • Bad Bunny's Super Bowl halftime show was many things: a time-traveling journey through the history of Puerto Rico, a statement of pan-American unity, and a masterpiece of cultural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results